Company Overview and News

0
TV actor Siddharth rams into three cars, arrested

21h freepressjournal.in
Mumbai : TV actor Siddharth Shukla has been arrested by Oshiwara police on Saturday evening in an accident case. Shukla was heavily speeding his BMW car when he rammed into three cars. Due to the collision, Shukla sustained minor injuries.
532652 KTKBANK WSTC

0
The Karnataka Bank Limited - Shareholders meeting

2018-07-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532652 KTKBANK

0
The Karnataka Bank Limited - Press Release

2018-07-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532652 KTKBANK

0
The Karnataka Bank Limited - Press Release

2018-07-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532652 KTKBANK

0
The Karnataka Bank Limited - Press Release

2018-07-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532652 KTKBANK

0
The Karnataka Bank Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532652 KTKBANK

0
Broker's call: Karnataka Bank (Buy)

2018-07-16 thehindubusinessline
In Q1FY19, Karnataka Bank’s (KBL) NII has improved by 10.4 per cent y-o-y to ₹468.6 crore but down 13.46 per cent q-o-q. It’s net profit for the quarter, which has come at ₹163.2 crore against ₹133.8 crore y-o-y, which is up by 22 per cent. NIMs for the quarter has improved by 3 bps y-o-y to 3 per cent. GNPA for Q1FY19 stood at 4.72 per cent against 4.92 per cent q-o-q, which has declined by 20 bps.
532652 500116 IDBI KTKBANK

0
Karnataka Bank shares jump nearly 5% after Q1 results

2018-07-12 thehindubusinessline
Shares of Karnataka Bank today surged nearly 5 per cent after the company posted 22 per cent rise in net profit for the quarter ended June 30.
532652 KTKBANK

0
The Karnataka Bank Limited - Press Release

2018-07-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532652 KTKBANK

0
The Karnataka Bank Limited - Financial Result Updates

2018-07-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532652 KTKBANK

0
Karnataka Bank, Cyient Q1 results on Thursday

2018-07-11 thehindubusinessline
The respective boards of Cyient and Karnataka Bank will meet on Thursday to consider their quarterly results for the period ended June. Also, the board of Talwalkars Lifestyles will meet on Thursday to consider its full-year and quarterly results for the period ended March 2018. Focus will be on the results of Karnataka Bank, which had reported a sharp fall of 92 per cent in Q4 net profit of the previous fiscal.
532652 KTKBANK

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...